文献速递瓣膜病与结构性心脏病

中危重度主动脉瓣狭窄患者TAVR与SAVR的健康状态获益:PARTNER 2随机临床试验结果

Health Status Benefits of Transcatheter vs Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Intermediate Surgical Risk: Results From the PARTNER 2 Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2017-01-01

PARTNER 2试验纳入2032例中危重度主动脉瓣狭窄患者,随机接受TAVR(Sapien XT瓣膜)或SAVR并随访2年。两组2年生存相似,健康状态均显著改善;TAVR仅在经股动脉入路患者中1个月时健康状态优于SAVR,1年和2年时无差异。

要点

  • 中危重度AS患者TAVR与SAVR后2年健康状态均显著改善。
  • TAVR早期健康状态优势仅见于经股动脉入路患者。
  • 1年和2年时TAVR与SAVR健康状态无显著差异。

核心结论

  • 中危重度AS患者接受TAVR或SAVR后2年内健康状态均显著改善。
  • TAVR早期健康状态改善更优,但仅见于经股动脉入路患者。
  • 1年和2年时TAVR与SAVR在任何健康状态指标上均无显著差异。

研究设计与样本

  • 患者随机接受TAVR(Sapien XT瓣膜)或SAVR,随访2年。
  • 主要分析队列为1833例有基线健康状态数据者(TAVR 950例,SAVR 883例)。
  • 平均(SD)年龄81.4(6.8)岁,男性1006例(54.9%)。

主要发现

  • 2年内TAVR和SAVR均与疾病特异性(KCCQ-OS量表16-22分)和通用健康状态(SF-36躯体摘要量表3.9-5.1分)显著改善相关。
  • 1个月时经股动脉入路患者TAVR的KCCQ-OS平均差异为14.1分(95%CI 11.7-16.4,P<.01)。
  • 1个月时经胸入路患者TAVR的KCCQ-OS平均差异为3.5分(95%CI -1.4至8.4,交互P<.01)。
  • 1年和2年时TAVR与SAVR在任何健康状态指标上均无显著差异。

临床怎么用

  • 中危重度AS患者选择TAVR或SAVR时,应告知两者2年健康状态获益相似。
  • 经股动脉入路TAVR可能带来早期健康状态优势,可结合入路评估个体化决策。

局限性

  • 需要更长期随访评估TAVR与SAVR生活质量改善的持久性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: In patients with severe aortic stenosis (AS) at intermediate surgical risk, treatment with transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR) results in similar 2-year survival. The effect of TAVR vs SAVR on health status in patients at intermediate surgical risk is unknown. OBJECTIVE: To compare health-related quality of life among intermediate-risk patients with severe AS treated with either TAVR or SAVR. DESIGN, SETTING, AND PARTICIPANTS: Between December 2011 and November 2013, 2032 intermediate-risk patients with severe AS were randomized to TAVR with the Sapien XT valve or SAVR in the Placement of Aortic Transcatheter Valve 2 Trial and were followed up for 2 years. Data analysis was conducted between March 1, 2016, to April 30, 2017. MAIN OUTCOMES AND MEASURES: Health status was assessed at baseline, 1 month, 1 year, and 2 years using the Kansas City Cardiomyopathy Questionnaire (KCCQ) (23 items covering physical function, social function, symptoms, self-efficacy and knowledge, and quality of life on a 0- to 100-point scale; higher scores indicate better quality of life), Medical Outcomes Study Short Form-36 (36 items covering 8 dimensions of health status as well as physical and mental summary scores; higher scores represent better health status), and EuroQOL-5D (assesses 5 dimensions of general health on a 3-level scale, with utility scores ranging from 0 [death] to 1 [ideal health]). Analysis of covariance was used to examine changes in health status over time, adjusting for baseline status. RESULTS: Of the 2032 randomized patients, baseline health status was available for 1833 individuals (950 TAVR, 883 SAVR) who formed the primary analytic cohort. A total of 1006 (54.9%) of the population were men; mean (SD) age was 81.4 (6.8) years. Over 2 years, both TAVR and SAVR were associated with significant improvements in both disease specific (16-22 points on the KCCQ-OS scale) and generic health status (3.9-5.1 points on the SF-36 physical summary scale). At 1 month, TAVR was associated with better health status than SAVR, but this difference was restricted to patients treated via transfemoral access (mean difference in the KCCQ overall summary [KCCQ-OS] score, 14.1 points; 95% CI, 11.7 to 16.4; P < .01) and was not seen in patients treated via transthoracic access (mean difference in KCCQ-OS, 3.5 points; 95% CI, -1.4 to 8.4; P < .01 for interaction). There were no significant differences between TAVR and SAVR in any health status measures at 1 or 2 years. CONCLUSIONS AND RELEVANCE: Among intermediate-risk patients with severe AS, health status improved significantly with both TAVR and SAVR through 2 years of follow up. Early health status improvement was greater with TAVR, but only among patients treated via transfemoral access. Longer term follow-up is needed to assess the durability of quality-of-life improvement with TAVR vs SAVR in this population. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01314313.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Baron SJ, Arnold SV, Wang K, et al. Health Status Benefits of Transcatheter vs Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Intermediate Surgical Risk: Results From the PARTNER 2 Randomized Clinical Trial. JAMA Cardiol. 2017. PMID: 28658491. doi:10.1001/jamacardio.2017.2039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。